Companies: Shionogi
Drugs: XOCOVA, ensitrelvir, Veklury, remdesivir
FDA Approves First Oral COVID-19 PEP Drug, Xocova
100% citation coverage1 regulatory sources
The FDA has approved Shionogi's Xocova (ensitrelvir) as the first oral post-exposure prophylaxis (PEP) for COVID-19 in adults and adolescents aged 12 years and older. The approval is based on the Phase 3 SCORPIO-PEP trial.
Executive Summary
- FDA approved Xocova (ensitrelvir) as the first oral post-exposure prophylaxis for COVID-19.
- Approval covers adults and adolescents aged 12 years and older.
- Based on Phase 3 SCORPIO-PEP trial data.
Show 1 more takeaway
- Shionogi gains a first-in-class oral PEP advantage in the COVID-19 market.
Market Impact
| Regulatory | high |
|---|---|
| Commercial | high |
| Competitive | medium |
| Investment | high |
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for XOCOVA.
Unlock full calendar →Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →FDA Approves First Oral COVID-19 PEP Drug, Xocova
The FDA has approved Shionogi's Xocova (ensitrelvir) as the first oral post-exposure prophylaxis (PEP) for COVID-19 in adults and adolescents aged 12 years and older. The approval is based on the Phase 3 SCORPIO-PEP trial, handing Shionogi a first-mover advantage in a new oral prevention segment that could reshape the pandemic response playbook for payers and health systems.
Key Takeaways
- FDA approved Xocova (ensitrelvir) as the first oral post-exposure prophylaxis for COVID-19.
- Approval covers adults and adolescents aged 12 years and older.
- Based on Phase 3 SCORPIO-PEP trial data.
- Shionogi gains a first-in-class oral PEP advantage in the COVID-19 market.
What did the FDA approve?
The U.S. FDA has approved Shionogi's Xocova (ensitrelvir) as the first oral post-exposure prophylaxis to help prevent COVID-19 in individuals aged 12 years and older who have been exposed to the virus. This marks a significant shift from the prior standard of care. Veklury (remdesivir) was the first drug approved to treat COVID-19, but it is administered intravenously for hospitalized patients. The approval is supported by the Phase 3 SCORPIO-PEP trial, which enrolled participants after a household or similar close exposure.
How does Xocova differ from Veklury?
Veklury (remdesivir) was the first drug approved to treat COVID-19, but it requires IV administration in a hospital setting. Xocova, by contrast, is an oral pill that patients can take at home after a known exposure. This convenience advantage could dramatically expand the addressable prevention market, especially for household contacts and healthcare workers who need rapid, non-invasive prophylaxis. The FDA's original approval of Veklury set the stage for treatment, but the agency's new decision opens a prevention pathway that did not previously exist in oral form.
What are the implications for pharma teams?
For BD teams, this approval opens a new oral PEP segment in the COVID-19 market, potentially reducing reliance on vaccines and monoclonal antibodies. Investors should note Shionogi's first-mover advantage and the potential for rapid uptake given the convenience of oral administration. Analysts should compare Xocova's efficacy and safety profile against emerging oral antivirals and monitor real-world effectiveness data. Competitive impact includes pressure on Gilead's Veklury and other late-stage oral candidates. The SCORPIO-PEP trial data will be critical for formulary decisions, and payers will likely demand head-to-head data against the standard of care.
Frequently Asked Questions
What is the first drug that was approved to treat COVID-19?
The U.S. Food and Drug Administration approved the antiviral drug Veklury (remdesivir) for use in adult and pediatric patients 12 years of age and older and weighing at least 40 kilograms (about 88 pounds) for the treatment of COVID-19 requiring hospitalization. That approval was for treatment, not prevention, and required IV administration — a key contrast with the new oral PEP option.
What is the basis for the Xocova approval?
FDA approval of Xocova was based on results of the Phase 3 SCORPIO-PEP (Stopping COVID-19 pRogression with early Protease InhibitOr treatment) trial. The trial demonstrated a statistically significant reduction in the risk of developing symptomatic COVID-19 among participants who received ensitrelvir compared to placebo after a known exposure.
What is the market potential for oral COVID-19 PEP?
The oral PEP segment targets a large population: anyone aged 12+ with a known exposure to COVID-19. This includes household contacts, healthcare workers, and other high-risk groups. With oral administration offering convenience over IV therapies and potentially lower cost than monoclonal antibodies, the segment could capture significant share of the prevention market, though real-world uptake will depend on pricing, payer coverage, and ongoing efficacy against circulating variants.
Related profiles
Related coverage
Follow XOCOVA developments
FDA covid-19 alerts and XOCOVA pipeline updates, every Monday.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
About the Author
Related Articles
Industry Reports & Whitepapers
- Barriers and Facilitators to Use of Digital Health Tools by Healthcare Practitioners — This study identifies key barriers and facilitators impacting healthcare practitioners' use of digit…